Navigation Links
China Health Resource Appoints USA Acquisition Counsel
Date:12/28/2011

SICHUAN, China, Dec. 28, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI), through its wholly owned subsidiary Suining Yinfa DAR Industrial Co, Ltd (Yinfa), announces it has appointed Loeb & Loeb LLP as its USA legal counsel for its 2012 acquisition initiative. Andrew Ross, a partner with New York-based law firm Loeb & Loeb LLP and Chair of the Mergers and Acquisition Practice Group and known for his international mergers & acquisitions, security and financing expertise, will lead as Loeb & Loeb counsel for CHRI's initiative.

"2011 has been a great year for the company in terms of financial performance as well as broadening of our products base. Borrowing from our unique pioneering position in setting TCM quality standard in using GAP for TCM products, this is our next strategic step for the company's expansion into the global markets beyond China. We are truly pleased that Mr. Andrew Ross of Loeb & Loeb is joining our acquisition team at CHRI. CHRI is capitalizing in the new trend of increased demand for healthcare products from an aging population in the major global economies like USA, Japan, China, Germany and Italy, the general increasing need for healthcare, and the increasing acceptance of alternative and preventive health care worldwide," said Jiayin Wang, the Chairman and CEO of CHRI.

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is the only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province. For more information visit www.chinahealthresource.com.

About Loeb & Loeb

Loeb & Loeb LLP is a multi-service law firm with more than 300 attorneys and six offices in Los Angeles, New York, Chicago, Nashville, Washington, DC, and Beijing. The firm's China Practice serves China-based companies and U.S. clients doing business in China in corporate and securities law, private equity and cross-border transactions. We are leaders in representing Asian companies seeking financing from U.S. capital markets or expanding into the U.S., as well as U.S. companies expanding their businesses or looking to invest in China. Our core areas of capability include mergers, acquisitions, joint ventures and licensing; initial, secondary and alternative public offerings; private equity and debt financings; going private transactions; corporate governance and securities litigation. For more information, visit www.loeb.com.

Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.


'/>"/>
SOURCE China Health Resource, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017 According to a new market research report "Neural Network ... Software), Vertical, and Region - Global Forecast to 2021" published by MarketsandMarkets, the ... by 2021, at a Compound Annual Growth Rate (CAGR) of 33.2%. ... ... MarketsandMarkets Logo ...
(Date:1/17/2017)... and KANSAS CITY, Mo. ... Hospitals Neonatal Consortium (CHNC) has selected Velos and ... visionary data management and multicenter initiatives. ... comprised of 32 Neonatal Intensive Care Units at ... . The consortium provides a benchmark of ...
(Date:1/17/2017)... --  Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, today ... and pharmaceutical development at Tocagen, will present at Phacilitate Cell ... in Miami . Details of ... ... viruses - what to do when and why Date and Time: ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, ... Cradle to Cradle Product Design Challenge , the Cradle to Cradle Products ... six circular design challenges scheduled to run through early 2018. The challenges are presented ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Neil H. ... financial planning assistance to communities throughout the region, is launching a charity drive to ... disease is by far the deadliest killer in America, and is responsible for 1 ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... SC&H Group, ... firm as a Principal in its IT Advisory Services practice . Rossi is ... months as market demand for strategic IT guidance grows, and the practice continues to ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... to visualize, detect, and eliminate cyber threats in real-time, today announced a strategic ... provider, headquartered in Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... families from two offices in Tyler, has announced the latest beneficiary of their ... Wish Network, a nonprofit organization dedicated to fulfilling the dreams of terminally ill ...
Breaking Medicine News(10 mins):